The ORBIT trial is part of a worldwide search for a functional cure of HIV. One such cure strategy aims to reverse HIV in the reservoir from latency by increasing cell-associated HIV-RNA, which will lead to increased antigen presentation, trigger immune recognition, and facilitate the elimination of reservoir cells (so-called 'shock and kill' approach to HIV cure). Participants of the trial are adults with HIV with undetectable viral load that are able to give informed consent to participate in the trial, in total 49 patients will be recruited. The investigational medical compounds in this trial are panobinostat, lenalidomide and pyrimethamine. These are all licensed drugs for other conditions. Participants of this trial will receive a single dose of the IMPs, either as monotherapy or as combination therapy. Sampling will be performed before, during and after medical treatment to evaluate latency reversal, reservoir reduction and safety endpoints. Patients will be recruited from the Erasmus MC, Amsterdam university Medical Center and the University Medical Center Utrecht.

Start Date01 Apr 2024

Sponsor / Collaborator

Erasmus MC

NCT05324501

/ TerminatedPhase 1

Phase I Open Label Ascending Dose Study to Assess the Feasibility and Safety of Intermittent Infusions of MTX110 Administered by Convection-Enhanced Delivery (CED) in Patients With Recurrent Glioblastoma (rGBM) (MAGIC-G1)

A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

Start Date19 Oct 2022

Sponsor / Collaborator

Biodexa Pharmaceuticals Plc

NCT05725200

/ RecruitingPhase 2IIT

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Start Date27 Sep 2022

Sponsor / Collaborator

Oslo universitetssykehus HF

100 Clinical Results associated with Panobinostat lactate

100 Translational Medicine associated with Panobinostat lactate

100 Patents (Medical) associated with Panobinostat lactate

1,991

Literatures (Medical) associated with Panobinostat lactate

01 Jan 2026·BIOMATERIALS

CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma

Article

Author: Li, Shannuo ; Al Faruque, Hasan ; Yang, Jiyuan ; Li, Jiahui ; Kopeček, Jindřich ; Sborov, Douglas W

Multiple myeloma (MM) remains a formidable disease, especially in relapsed or refractory cases when there are limited treatment options. In this study, we introduce two polymer-antibody drug conjugates (pADCs), ISA-P-EPI (U6244-021) and DARA-P-EPI (U6244-031), which contain semitelechelic N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin (EPI) conjugate attached to CD38-targeting antibodies Isatuximab (ISA) and Daratumumab (DARA). These pADCs enhance therapeutic efficacy by combining the specificity of ISA and DARA with the cytotoxic potency of EPI while preserving antibody function. The EPI is linked to the HPMA polymer backbone via a tetrapeptide spacer cleavable by lysosomal enzymes, enabling drug release upon endocytosis within tumor cells. This design achieves a higher drug-to-antibody ratio than conventional ADCs for safer delivery of drug payload. In vitro studies demonstrate efficient binding, internalization, and cytotoxic efficacy of these pADCs in MM cell lines. Mechanistic investigations revealed significant therapeutic effects, including cell cycle arrest, immunogenic cell death, and preserved antibody-dependent cellular cytotoxicity (ADCC). In addition, pADCs were effective in 5 out of 8 primary samples, with their efficacy closely correlating with CD38 surface expression levels. To enhance therapeutic outcomes, we employed panobinostat to upregulate CD38 expression, which further improved pADC efficacy. In a preclinical NRG mouse model inoculated with MM.1S-luc cells, pADC treatment significantly delayed tumor progression and prolonged survival, with all treated mice remaining alive at the 100-day endpoint. These findings underscore the potential of CD38-targeted pADCs as a novel approach to combining chemotherapy with immunotherapy for MM treatment, warranting further investigation into their optimization and clinical application.

01 Aug 2025·Blood Neoplasia

Ambroxol induces myeloma cell death by inhibiting autophagy

Article

Author: Hattori, Yutaka ; Yamaguchi, Takashi ; Shibata, Shinsuke ; Kunieda, Hisako ; Sugiyama, Hiromu ; Okaue, Taiga ; Yamada, Taketo ; Matsushita, Maiko ; Saya, Hideyuki ; Matsumoto, Yoshinao ; Yamamoto, Tomofumi ; Yamazaki, Kohei ; Miyashita, Yamato

In the last decade, newly developed drugs have significantly improved the prognosis of patients with multiple myeloma (MM). However, most patients relapse sooner or later, and thus MM remains an incurable hematological malignancy. In addition, serious adverse events occasionally hamper the continuation of treatment. Exploitation of new drugs that potentiate antitumor activities and alleviate the adverse effects of existing drugs is needed. Here, we found through drug repositioning that ambroxol hydrochloride (ambroxol) induces apoptosis of MM cells. Interestingly, turnover and reporter assays revealed that ambroxol inhibits the late stage of autophagy. Transmission electron microscopy observation also revealed that MM cells treated with ambroxol accumulated autophagic vacuoles in the cytoplasm, further supporting the inhibition of late-stage autophagy. Existing anti-MM drugs demonstrate various effects on autophagy; panobinostat, a histone deacetylase inhibitor, induces autophagy, whereas bortezomib and lenalidomide do not. When administered together, ambroxol and panobinostat exhibited a synergistic antimyeloma effect, likely due to ambroxol inhibiting the activation of panobinostat-induced autophagy while downregulating MCL-1 expression. In the KMS11 xenograft model, ambroxol significantly delayed tumor growth when administered alone; when co-administered with panobinostat, ambroxol synergistically enhanced the panobinostat-induced inhibition of tumor growth. Interestingly, concomitant use of ambroxol and panobinostat alleviated panobinostat-induced diarrhea. Gene set enrichment and pathway analyses also revealed that ambroxol increased the expression of genes related to autophagy inhibition and unfolded protein response. These results suggested that autophagy is a promising therapeutic target for MM.

02 Jul 2025·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A propidium iodide-based in vitro screen of the "Bug Box" against Babesia duncani reveals potent inhibitors.

Article

Author: Hyson, Peter R ; Meyers, Marvin J ; Huston, Christopher D ; Dews, Emmett A ; Teixeira, José E

The incidence and endemic range of human babesiosis are expanding. Standard therapy for human babesiosis consists of antimicrobials developed for other indications. While these treatments are adequate in immunocompetent hosts, infections in the immunocompromised can be severe, relapsing, and drug-resistant despite the use of multi-drug regimens. Existing drugs are ineffective in the immunocompromised because they cannot achieve and maintain adequate serum concentrations to inhibit Babesia. Discovery of improved agents against Babesia spp. is of growing importance, and efficient techniques for high-throughput compound screening can assist in this effort. We developed a high-throughput in vitro drug screening assay for Babesia duncani that is conducted in 384-well plates and makes use of the fluorescent DNA stain propidium iodide (PI) with relative fluorescence measured by a microplate reader. A Z' factor of 0.82 was calculated, which suggests an excellent ability to detect inhibitory compounds. A screen of the 41-compound library Structural Genomics Consortium Bug Box was conducted, yielding five hits: trimethoprim, atovaquone, SDDC M7, diphenyleneiodonium chloride, and panobinostat. Panobinostat, a histone deacetylase complex (HDAC) inhibitor, was selected for further evaluation given that its target had not been previously explored in B. duncani. Dose-response testing of structurally related compounds revealed multiple potential leads, including nanatinostat and quisinostat, both of which were potent at the nanomolar level and showed favorable selectivity index in cytotoxicity studies. High-throughput screening using PI and 384-well plates is an advance in drug discovery for babesiosis, and HDAC inhibitors show promise as lead compounds worthy of further investigation.

News (Medical) associated with Panobinostat lactate

27 Jun 2025

·www.globenewswire.com

Results of Annual General Meeting

June 27, 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company’s shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company's website at https://biodexapharma.com/investors/corporate-governance//#agms. About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer: tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com. Forward-Looking Statements Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.

26 Jun 2025

·www.globenewswire.com

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the activation of the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis (FAP). The trial, which is now enrolling, represents a significant milestone in the development of a potential new treatment option for FAP. The Serenta trial (NCT06950385) is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of eRapa in individuals diagnosed with FAP. The first site, in the US, is now open and actively screening eligible participants. Commenting, Stephen Stamp CEO and CFO of Biodexa said “Following Fast Track Designation, a positive Type C Meeting and launch of a dedicated website for patients, onboarding our first clinical site represents an important milestone for our eRapa Phase 3 program in FAP. Congratulations to our team, our collaborators at Emtora Biosciences and our CRO, LumaBridge. This would not have been possible without the support of CPRIT which has awarded $20 million in grant funding to support the program”. Familial adenomatous polyposis is a rare, inherited disorder characterized by the development of hundreds to thousands of colorectal polyps and a near-100% lifetime risk of colorectal cancer if left untreated. There is a significant unmet need for effective, less invasive therapies for FAP patients. FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. If untreated, FAP typically leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with a reported prevalence of one in 5,000 to 10,000 in the US1 and one in 11,300 to 37,600 in Europe2. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP. eRapa is a proprietary oral formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis3. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035. To date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs. CPRIT has recruited 237 distinguished researchers, supported the establishment, expansion or relocation of 43 companies to Texas and generated over $5.7 billion in additional public and private investment. CPRIT funding has advanced scientific and clinical knowledge and provided 7.4 million life-saving cancer prevention and early detection services reaching Texans from all 254 counties. On November 5, 2019, Texas voters overwhelmingly approved a constitutional amendment to provide an additional $3 billion to CPRIT for a total $6 billion investment in cancer research and prevention. 1. www.rarediseases.org 2. www.orpha.net 3. Tian et al., mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy, Int J Mol Sci. 2019 Feb; 20(3): 755 Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. The content above comes from the network. if any infringement, please contact us to modify.

Fast TrackDrug Approval

05 Jun 2025

·www.globenewswire.com

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes (“T1D”). The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course. Tolimidone’s potential utility in T1D has been demonstrated by a number of preclinical studies conducted at the University of Alberta, where Lyn kinase was identified as a key factor for beta cell survival and proliferation in in vitro and in vivo models. Most importantly, tolimidone was able to induce proliferation in beta cells isolated from human cadavers. Tolimidone was originally discovered by Pfizer Inc. (“Pfizer”) and was developed through Phase II for the treatment of gastric ulcers. Pfizer undertook a broad pre-clinical program to characterize the pharmacology, pharmacokinetics, metabolism and toxicology of tolimidone. Pfizer discontinued development of the drug due to lack of efficacy for that indication in a Phase 2 clinical trial. Tolimidone is a selective activator of the enzyme Lyn kinase which increases phosphorylation of insulin substrate -1, thereby amplifying the signalling cascade initiated by the binding of insulin to its receptor. Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.】】 MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Study

100 Deals associated with Panobinostat lactate

External Link

KEGG	Wiki	ATC	Drug Bank
D10019	Panobinostat lactate	L01XX42	DB06603

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	United States	Secura Bio, Inc.	23 Feb 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hodgkin's Lymphoma	Phase 3	United States	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	Australia	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	Belgium	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	Brazil	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	Canada	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	France	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	Germany	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	Israel	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	Italy	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	Netherlands	Novartis Pharmaceuticals Corp.	01 Jun 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04804709 (CTgov)	Phase 1	Diffuse midline glioma, point mutation K27M in histone H3 \| Diffuse Intrinsic Pontine Glioma	5	Focused Ultrasound with neuro-navigator-controlled sonication+Panobinostat 15 MG	cwbhftgyci = pbylbipnez gmkykkepur (elnuxsateh, vilvtguzqe - rwlukvqrdl) View more	-	08 Jun 2025
NCT05324501 (MAGIC-G1, GlobeNewswire) Manual	Phase 1	Recurrent Glioblastoma	4	MTX110 (Cohort A)	whwwjozwpi(mvycjjyizz) = vrvzciwqky npjwqkxunw (jaczwnsjdw )	Positive	04 Oct 2024
NCT02654990 (PANORAMA 3 \| PANORAMA_3, CTgov)	Phase 2	Multiple Myeloma	248	Panobinostat (Arm A - Panobinostat (20 mg, TIW))	mfsmsgtjyi = edbbscaufq wnwfxrskoj (idjlggfudi, ozjmawacgj - gkwrcdbkcc) View more	-	12 Jul 2024
NCT02654990 (PANORAMA 3 \| PANORAMA_3, CTgov)	Phase 2	Multiple Myeloma	248	Panobinostat (Arm B - Panobinostat (20 mg, BIW))	mfsmsgtjyi = bjdajkmttk wnwfxrskoj (idjlggfudi, eclhdhrxaq - lluilxyirq) View more	-	12 Jul 2024
NCT04264143 (Biospace) Manual	Phase 1	Diffuse Midline Glioma	9	MTX110	ihcmhmntzt(ibmhqysjkt) = tqfewpbqmk uflndisqir (rvqymhrhcy, 8 - 20) View more	Positive	02 Jul 2024
NCT02471430 (ACTIVATE, CTgov)	Phase 1/2	HIV Seropositivity	17	Panobinostat (Arm A)	lavyqmwnnj = lpaqkvwwnt euxcqjmcch (dofjppoqzz, zjavsimcsh - qjthqlmycb) View more	-	28 Feb 2024
NCT02471430 (ACTIVATE, CTgov)	Phase 1/2	HIV Seropositivity	17	Panobinostat+Pegylated Interferon-alpha2a (Arm B)	lavyqmwnnj = hequzdhxlo euxcqjmcch (dofjppoqzz, wbhqwhtdeh - vpnctavgre) View more	-	28 Feb 2024
NCT04264143 (GlobeNewswire) Manual	Phase 1	Diffuse Midline Glioma	9	MTX110	rglejsemxj(xhnvxylrbx) = ptwjzbbddh knxxexapmv (ulnqcxxwjr )	Positive	23 Feb 2024
NCT02506959 (Tandem Meetings ASTCT and CIBMTR2023)	Phase 2	Bone Marrow Neoplasms del(17p) \| t(4;14) \| t(14;16) ... View more	80	Pano/GemBuMel	odkpztconc(emzfmokxsq) = aajoaixhzp rhxzqntkxl (wbizlkutcy ) View more	Positive	01 Feb 2023
NCT03256045 (CTgov)	Phase 2	Recurrent Multiple Myeloma \| Relapse multiple myeloma \| Refractory Multiple Myeloma	9	Panobinostat+Carfilzomib+Dexamethasone	dsztchwozk = uicsunatbd oneyamztbc (atyoywfdvh, jzmwzowvub - qqvrcpziab) View more	-	09 May 2022
NCT03566199 (PNOC015, CTgov)	Phase 1/2	Diffuse Intrinsic Pontine Glioma	7	MTX110	djagdyfdno = tnqxgmyqww oecanqyoqg (bozwwusnuw, gmsugslail - zcnijtsmjy) View more	-	25 Feb 2022
NCT01496118 (CTgov)	Phase 1/2	Relapse multiple myeloma \| Refractory Multiple Myeloma	80	panobinostat+Carfilzomib (Dose Level 1)	vjnepxhjvo = nycpnjkxkf mrwctmzgvb (bqdmpaappu, tubbjxsgxl - qmiupkzwuh) View more	-	02 Feb 2022
NCT01496118 (CTgov)	Phase 1/2	Relapse multiple myeloma \| Refractory Multiple Myeloma	80	panobinostat+Carfilzomib (Dose Level 2)	vjnepxhjvo = xiectmabcy mrwctmzgvb (bqdmpaappu, rxhmbuccuv - tejnyyluor) View more	-	02 Feb 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis